Zinodap M 10/1000 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 1000 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus to improve glycemic control in adults when diet and exercise alone do not provide adequate control. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Zinodap M 10/1000 should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Common adverse effects may include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare cases of lactic acidosis. This combination therapy offers a complementary mechanism of action, providing effective glycemic control and potential cardiovascular benefits in patients with type 2 diabetes mellitus.